{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:07:51Z","timestamp":1795172871231,"version":"4.10.3"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"7909","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2022,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced owing to emerging variants of concern\n                    <jats:sup>1,2<\/jats:sup>\n                    . Development of host-directed therapeutics and prophylactics could limit such resistance and offer urgently needed protection against variants of concern\n                    <jats:sup>3,4<\/jats:sup>\n                    . Attractive pharmacological targets to impede viral entry include type-II transmembrane serine proteases (TTSPs) such as TMPRSS2; these proteases cleave the viral spike protein to expose the fusion peptide for cell entry, and thus have an essential role in the virus lifecycle\n                    <jats:sup>5,6<\/jats:sup>\n                    . Here we identify and characterize a small-molecule compound, N-0385, which exhibits low nanomolar potency and a selectivity index of higher than 10\n                    <jats:sup>6<\/jats:sup>\n                    in inhibiting SARS-CoV-2 infection in human lung cells and in donor-derived colonoids\n                    <jats:sup>7<\/jats:sup>\n                    . In Calu-3 cells it inhibits the entry of the SARS-CoV-2 variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta). Notably, in the K18-human ACE2 transgenic mouse model of severe COVID-19, we found that N-0385 affords a high level of prophylactic and therapeutic benefit after multiple administrations or even after a single administration. Together, our findings show that TTSP-mediated proteolytic maturation of the spike protein is critical for SARS-CoV-2 infection in vivo, and suggest that N-0385 provides an effective early treatment option against COVID-19 and emerging SARS-CoV-2 variants of concern.\n                  <\/jats:p>","DOI":"10.1038\/s41586-022-04661-w","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T06:22:53Z","timestamp":1648448573000},"page":"340-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":223,"title":["A\ufeff TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic"],"prefix":"10.1038","volume":"605","author":[{"given":"Tirosh","family":"Shapira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0521-9063","authenticated-orcid":false,"given":"I. Abrrey","family":"Monreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8961-0782","authenticated-orcid":false,"given":"S\u00e9bastien P.","family":"Dion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8874-6648","authenticated-orcid":false,"given":"David W.","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Imbiakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-1291","authenticated-orcid":false,"given":"Andrea D.","family":"Olmstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6036-9895","authenticated-orcid":false,"given":"Mason","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-5564","authenticated-orcid":false,"given":"Antoine","family":"D\u00e9silets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8290-5756","authenticated-orcid":false,"given":"Mathias","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Vandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor A. H.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaleigha","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-3068","authenticated-orcid":false,"given":"William D.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0670-0513","authenticated-orcid":false,"given":"Ivan Robert","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Marsault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Sahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego G.","family":"Diel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-8029","authenticated-orcid":false,"given":"Gerlinde R.","family":"Van de Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4968-3415","authenticated-orcid":false,"given":"Avery","family":"August","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-7970","authenticated-orcid":false,"given":"Pierre-Luc","family":"Boudreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-8003","authenticated-orcid":false,"given":"Richard","family":"Leduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-8360","authenticated-orcid":false,"given":"Hector C.","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6148-7460","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"key":"4661_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2021).","journal-title":"Nature"},{"key":"4661_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757\u2013773 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"4661_CR3","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA 117, 11727\u201311734 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4661_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"4661_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1126\/science.abg6837","volume":"371","author":"JP Wong","year":"2021","unstructured":"Wong, J. P. & Damania, B. SARS-CoV-2 dependence on host pathways. Science 371, 884\u2013885 (2021).","journal-title":"Science"},{"key":"4661_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2022","unstructured":"Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3\u201320 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"4661_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/ecco-jcc\/jjz194","volume":"14","author":"WD Rees","year":"2020","unstructured":"Rees, W. D. et al. Enteroids derived from inflammatory bowel disease patients display dysregulated endoplasmic reticulum stress pathways, leading to differential inflammatory responses and dendritic cell maturation. J. Crohns Colitis 14, 948\u2013961 (2020).","journal-title":"J. Crohns Colitis"},{"key":"4661_CR8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"4661_CR9","unstructured":"COVID-19 Dashboard. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University https:\/\/coronavirus.jhu.edu\/map.html."},{"key":"4661_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/d41586-021-03619-8","volume":"600","author":"E Callaway","year":"2021","unstructured":"Callaway, E. Beyond Omicron: what\u2019s next for COVID\u2019s viral evolution. Nature 600, 204\u2013207 (2021).","journal-title":"Nature"},{"key":"4661_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.chom.2021.02.020","volume":"29","author":"JA Plante","year":"2021","unstructured":"Plante, J. A. et al. The variant gambit: COVID-19\u2019s next move. Cell Host Microbe 29, 508\u2013515 (2021).","journal-title":"Cell Host Microbe"},{"key":"4661_CR12","doi-asserted-by":"publisher","first-page":"eabn7842","DOI":"10.1126\/scitranslmed.abn7842","volume":"14","author":"BL Sievers","year":"2022","unstructured":"Sievers, B. L. et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci. Transl. Med. 14, eabn7842 (2022).","journal-title":"Sci. Transl. Med."},{"key":"4661_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02476-9","volume":"18","author":"VC Chitalia","year":"2020","unstructured":"Chitalia, V. C. & Munawar, A. H. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. J. Transl. Med. 18, 390 (2020).","journal-title":"J. Transl. Med."},{"key":"4661_CR14","doi-asserted-by":"publisher","first-page":"e1009225","DOI":"10.1371\/journal.ppat.1009225","volume":"17","author":"N Murgolo","year":"2021","unstructured":"Murgolo, N. et al. SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development. PLoS Pathog. 17, e1009225 (2021).","journal-title":"PLoS Pathog."},{"key":"4661_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20542-0","volume":"12","author":"G Kokic","year":"2021","unstructured":"Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 12, 279 (2021).","journal-title":"Nat. Commun."},{"key":"4661_CR16","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4661_CR17","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"4661_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","volume":"591","author":"A Wahl","year":"2021","unstructured":"Wahl, A. et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 591, 451\u2013457 (2021).","journal-title":"Nature"},{"key":"4661_CR19","doi-asserted-by":"publisher","first-page":"100849","DOI":"10.1016\/j.eclinm.2021.100849","volume":"35","author":"JD Gunst","year":"2021","unstructured":"Gunst, J. D. et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. eClinicalMedicine 35, 100849 (2021).","journal-title":"eClinicalMedicine"},{"key":"4661_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25729-7","volume":"12","author":"J Beumer","year":"2021","unstructured":"Beumer, J. et al. A CRISPR\/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. Nat. Commun. 12, 5498 (2021).","journal-title":"Nat. Commun."},{"key":"4661_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","volume":"78","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M., Kleine-Weber, H. & P\u00f6hlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779\u2013784 (2020).","journal-title":"Mol. Cell"},{"key":"4661_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/acsinfecdis.0c00701","volume":"7","author":"T Tang","year":"2021","unstructured":"Tang, T. et al. Proteolytic activation of SARS-CoV-2 spike at the S1\/S2 boundary: potential role of proteases beyond furin. ACS Infect. Dis. 7, 264\u2013272 (2021).","journal-title":"ACS Infect. Dis."},{"key":"4661_CR23","doi-asserted-by":"publisher","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","volume":"65","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. eBioMedicine 65, 103255 (2021).","journal-title":"eBioMedicine"},{"key":"4661_CR24","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1080\/22221751.2020.1838955","volume":"9","author":"R Rathnasinghe","year":"2020","unstructured":"Rathnasinghe, R. et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerging Microbes Infect. 9, 2433\u20132445 (2020).","journal-title":"Emerging Microbes Infect."},{"key":"4661_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.abf4058","volume":"371","author":"KM White","year":"2021","unstructured":"White, K. M. et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science 371, 926\u2013931 (2021).","journal-title":"Science"},{"key":"4661_CR26","doi-asserted-by":"crossref","unstructured":"Dampalla, C. S. et al. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc. Natl Acad. Sci. USA 118, e2101555118 (2021).","DOI":"10.1073\/pnas.2101555118"},{"key":"4661_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1021\/ml3000534","volume":"3","author":"\u00c9 Colombo","year":"2012","unstructured":"Colombo, \u00c9. et al. Design and synthesis of potent, selective inhibitors of matriptase. ACS Med. Chem. Lett. 3, 530\u2013534 (2012).","journal-title":"ACS Med. Chem. Lett."},{"key":"4661_CR28","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1128\/JVI.03005-12","volume":"87","author":"A Beaulieu","year":"2013","unstructured":"Beaulieu, A. et al. Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium. J. Virol. 87, 4237\u20134251 (2013).","journal-title":"J. Virol."},{"key":"4661_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejmech.2017.02.006","volume":"129","author":"C St-Georges","year":"2017","unstructured":"St-Georges, C. et al. Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids. Eur. J. Med. Chem. 129, 110\u2013123 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"4661_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/13543776.2020.1817390","volume":"30","author":"A Murza","year":"2020","unstructured":"Murza, A. et al. Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract\u2013a review of patent literature. Expert Opin. Ther. Pat. 30, 807\u2013824 (2020).","journal-title":"Expert Opin. Ther. Pat."},{"key":"4661_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1021\/acsptsci.0c00106","volume":"3","author":"JH Shrimp","year":"2020","unstructured":"Shrimp, J. H. et al. An enzymatic TMPRSS2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of COVID-19. ACS Pharmacol. Transl. Sci. 3, 997\u20131007 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"4661_CR32","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.chembiol.2019.09.004","volume":"26","author":"F B\u00e9liveau","year":"2019","unstructured":"B\u00e9liveau, F. et al. Discovery and development of TMPRSS6 inhibitors modulating hepcidin levels in human hepatocytes. Cell Chem. Biol. 26, 1559\u20131572 (2019).","journal-title":"Cell Chem. Biol."},{"key":"4661_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77170-3","volume":"10","author":"RKM Long","year":"2020","unstructured":"Long, R. K. M. et al. Super resolution microscopy and deep learning identify Zika virus reorganization of the endoplasmic reticulum. Sci. Rep. 10, 20937 (2020).","journal-title":"Sci. Rep."},{"key":"4661_CR34","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1002\/cpim.113","volume":"131","author":"JF Staab","year":"2020","unstructured":"Staab, J. F., Lemme-Dumit, J. M., Latanich, R., Pasetti, M. F. & Zachos, N. C. Co-culture system of human enteroids\/colonoids with innate immune cells. Curr. Protoc. Immunol. 131, e113 (2020).","journal-title":"Curr. Protoc. Immunol."},{"key":"4661_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.abc1669","volume":"369","author":"MM Lamers","year":"2020","unstructured":"Lamers, M. M. et al. SARS-CoV-2 productively infects human gut enterocytes. Science 369, 50\u201354 (2020).","journal-title":"Science"},{"key":"4661_CR36","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"4661_CR37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray","year":"2007","unstructured":"McCray, P. B. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"4661_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41385-020-00340-z","volume":"13","author":"MD Johansen","year":"2020","unstructured":"Johansen, M. D. et al. Animal and translational models of SARS-CoV-2 infection and COVID-19. Mucosal Immunol. 13, 877\u2013891 (2020).","journal-title":"Mucosal Immunol."},{"key":"4661_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89013-w","volume":"11","author":"CJ C\u00e1ceres","year":"2021","unstructured":"C\u00e1ceres, C. J. et al. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci. Rep. 11, 9609 (2021).","journal-title":"Sci. Rep."},{"key":"4661_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coviro.2017.03.018","volume":"24","author":"M Laporte","year":"2017","unstructured":"Laporte, M. & Naesens, L. Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Curr. Opin. Virol. 24, 16\u201324 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"4661_CR41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000513040","volume":"209","author":"M Klingenstein","year":"2020","unstructured":"Klingenstein, M. et al. Evidence of SARS-CoV2 entry protein ACE2 in the human nose and olfactory bulb. Cells Tissues Organs 209, 155\u2013164 (2020).","journal-title":"Cells Tissues Organs"},{"key":"4661_CR42","doi-asserted-by":"publisher","first-page":"e105114","DOI":"10.15252\/embj.2020105114","volume":"39","author":"S Lukassen","year":"2020","unstructured":"Lukassen, S. et al. SARS\u2010CoV\u20102 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 39, e105114 (2020).","journal-title":"EMBO J."},{"key":"4661_CR43","doi-asserted-by":"publisher","first-page":"e1003774","DOI":"10.1371\/journal.ppat.1003774","volume":"9","author":"B Hatesuer","year":"2013","unstructured":"Hatesuer, B. et al. Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. PLoS Pathog. 9, e1003774 (2013).","journal-title":"PLoS Pathog."},{"key":"4661_CR44","doi-asserted-by":"publisher","first-page":"e2108728118","DOI":"10.1073\/pnas.2108728118","volume":"118","author":"M Mahoney","year":"2021","unstructured":"Mahoney, M. et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc. Natl Acad. Sci. USA 118, e2108728118 (2021).","journal-title":"Proc. Natl Acad. Sci."},{"key":"4661_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-020-00272-6","volume":"14","author":"C Lutz","year":"2020","unstructured":"Lutz, C., Maher, L., Lee, C. & Kang, W. COVID-19 preclinical models: Human angiotensin-converting enzyme 2 transgenic mice. Hum. Genomics 14, 20 (2020).","journal-title":"Hum. Genomics"},{"key":"4661_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3897\/rrpharmacology.6.53633","volume":"6","author":"VO Soldatov","year":"2020","unstructured":"Soldatov, V. O., Kubekina, M. V., Silaeva, Y. Y., Bruter, A. V. & Deykin, A. V. On the way from SARS-CoV-sensitive mice to murine COVID-19 model. Res. Results Pharmacol. 6, 1\u20137 (2020).","journal-title":"Res. Results Pharmacol."},{"key":"4661_CR47","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1177\/0194599820933170","volume":"163","author":"H TS","year":"2020","unstructured":"TS, H. et al. Intranasal antiviral drug delivery and coronavirus disease 2019 (COVID-19): a state of the art review. Otolaryngol. Head Neck Surg. 163, 682\u2013694 (2020).","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"4661_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41385-020-00359-2","volume":"14","author":"O Gallo","year":"2021","unstructured":"Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L. & Annunziato, F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunol. 14, 305\u2013316 (2021).","journal-title":"Mucosal Immunol."},{"key":"4661_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151, F., Bors, L. A., Farkas, D., Bajza, \u00c1. & Gizurarson, S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 143, 155\u2013170 (2018).","journal-title":"Brain Res. Bull."},{"key":"4661_CR50","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.abf4896","volume":"371","author":"RD de Vries","year":"2021","unstructured":"de Vries, R. D. et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 371, 1379\u20131382 (2021).","journal-title":"Science"},{"key":"4661_CR51","doi-asserted-by":"publisher","first-page":"e147973","DOI":"10.1172\/JCI147973","volume":"131","author":"YJ Sun","year":"2021","unstructured":"Sun, Y. J. et al. Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice. J. Clin. Invest. 131, e147973 (2021).","journal-title":"J. Clin. Invest."},{"key":"4661_CR52","first-page":"L493","volume":"266","author":"BQ Shen","year":"1994","unstructured":"Shen, B. Q., Finkbeiner, W. E., Wine, J. J., Mrsny, R. J. & Widdicombe, J. H. Calu-3: a human airway epithelial cell line that shows cAMP-dependent Cl\u2212 secretion. Am. J. Physiol. 266, L493\u2013L501 (1994).","journal-title":"Am. J. Physiol."},{"key":"4661_CR53","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10822-012-9570-1","volume":"26","author":"CR Corbeil","year":"2012","unstructured":"Corbeil, C. R., Williams, C. I. & Labute, P. Variability in docking success rates due to dataset preparation. J. Comput. Aided Mol. Des. 26, 775\u2013786 (2012).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"4661_CR54","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1099\/jgv.0.001453","volume":"101","author":"NS Ogando","year":"2020","unstructured":"Ogando, N. S. et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol. 101, 925\u2013940 (2020).","journal-title":"J. Gen. Virol."},{"key":"4661_CR55","doi-asserted-by":"publisher","first-page":"553962","DOI":"10.3389\/fmicb.2020.553962","volume":"11","author":"T Shapira","year":"2020","unstructured":"Shapira, T. et al. High-content screening of eukaryotic kinase inhibitors identify CHK2 inhibitor activity against Mycobacterium tuberculosis. Front. Microbiol. 11, 553962 (2020).","journal-title":"Front. Microbiol."},{"key":"4661_CR56","doi-asserted-by":"publisher","first-page":"e1002468","DOI":"10.1371\/journal.ppat.1002468","volume":"8","author":"AD Olmstead","year":"2012","unstructured":"Olmstead, A. D., Knecht, W., Lazarov, I., Dixit, S. B. & Jean, F. Human subtilase SKI-1\/S1P is a master regulator of the HCV lifecycle and a potential host cell target for developing indirect-acting antiviral agents. PLoS Pathog. 8, e1002468 (2012).","journal-title":"PLoS Pathog."},{"key":"4661_CR57","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.febslet.2006.03.030","volume":"580","author":"A D\u00e9silets","year":"2006","unstructured":"D\u00e9silets, A., Longpr\u00e9, J. M., Beaulieu, M. \u00c8. & Leduc, R. Inhibition of human matriptase by eglin c variants. FEBS Lett. 580, 2227\u20132232 (2006).","journal-title":"FEBS Lett."},{"key":"4661_CR58","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/j.1742-4658.2009.06950.x","volume":"276","author":"F B\u00e9liveau","year":"2009","unstructured":"B\u00e9liveau, F., D\u00e9silets, A. & Leduc, R. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides. FEBS J. 276, 2213\u20132226 (2009).","journal-title":"FEBS J."},{"key":"4661_CR59","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1261\/rna.1877010","volume":"16","author":"J-P Brosseau","year":"2010","unstructured":"Brosseau, J.-P. et al. High-throughput quantification of splicing isoforms. RNA 16, 442\u2013449 (2010).","journal-title":"RNA"},{"key":"4661_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2007-8-2-r19","volume":"8","author":"J Hellemans","year":"2007","unstructured":"Hellemans, J., Mortier, G., De Paepe, A., Speleman, F. & Vandesompele, J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 8, R19 (2007).","journal-title":"Genome Biol."},{"key":"4661_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19891-7","volume":"11","author":"FS Oladunni","year":"2020","unstructured":"Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 6122 (2020).","journal-title":"Nat. Commun."},{"key":"4661_CR62","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","volume":"589","author":"J Zheng","year":"2021","unstructured":"Zheng, J. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature 589, 603\u2013607 (2021).","journal-title":"Nature"},{"key":"4661_CR63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/9780470942390.mo110217","volume":"2","author":"T Burkholder","year":"2012","unstructured":"Burkholder, T., Foltz, C., Karlsson, E., Linton, C. G. & Smith, J. M. Health evaluation of experimental laboratory mice. Curr. Protoc. Mouse Biol. 2, 145\u2013165 (2012).","journal-title":"Curr. Protoc. Mouse Biol."},{"key":"4661_CR64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-0716-0211-9_16","volume":"2099","author":"DK Meyerholz","year":"2020","unstructured":"Meyerholz, D. K. & Beck, A. P. Histopathologic evaluation and scoring of viral lung infection. Methods Mol. Biol. 2099, 205\u2013220 (2020).","journal-title":"Methods Mol. Biol."},{"key":"4661_CR65","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1109\/TPAMI.2012.120","volume":"34","author":"R Achanta","year":"2012","unstructured":"Achanta, R. et al. SLIC superpixels compared to state-of-the-art superpixel methods. IEEE Trans. Pattern Anal. Mach. Intell. 34, 2274\u20132281 (2012).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"4661_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"4661_CR67","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1021\/acs.jmedchem.1c00481","volume":"64","author":"P Sarret","year":"2021","unstructured":"Sarret, P. \u00c9ric Marsault (1971\u20132021): a legacy through the prism of relationship chemistry. J. Med. Chem. 64, 5221\u20135224 (2021).","journal-title":"J. Med. Chem."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04661-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04661-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04661-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T09:13:46Z","timestamp":1652260426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04661-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":67,"journal-issue":{"issue":"7909","published-print":{"date-parts":[[2022,5,12]]}},"alternative-id":["4661"],"URL":"https:\/\/doi.org\/10.1038\/s41586-022-04661-w","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"14 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.-L.B. and R.L. are inventors on patent applications (US9365853B2 and US10988505B2) that cover matriptase and other type II transmembrane serine proteases inhibitors for treating and preventing viral infections, respiratory disorders, inflammatory disorders, pain disorders, tissue disorders, hyperproliferative disorders, and disorders associated with iron overload. The remaining authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}